Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TG 1042

Drug Profile

TG 1042

Alternative Names: Ad-IFNγ; Adenovirus interferon gamma; ASN 002 - Ascend; TG-1042

Latest Information Update: 19 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene
  • Developer Ascend Biopharmaceuticals; Nantes University Hospital; Transgene
  • Class Antineoplastics; Gene therapies; Immunotherapies; Interferons
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Basal cell nevus syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Basal cell cancer
  • No development reported Malignant melanoma
  • Discontinued Cutaneous B-cell lymphoma; Cutaneous T-cell lymphoma

Most Recent Events

  • 25 Sep 2019 Ascend Biopharmaceuticals plans a phase IIa trial for Basal cell cancer in Australia in October 2019 (ACTRN12619001298101)
  • 03 Jun 2018 Ascend Biopharmaceuticals suspends a phase I/II trial as another protocol is being developed in Basal cell cancer in USA (Intratumoural) (NCT03208296)
  • 14 Dec 2017 Ascend Biopharmaceuticals completes a phase I/II trial in Basal cell cancer in Australia (Intratumoural) (NCT02550678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top